Simeprevir and PR was significantly superior to placebo and PR ; rates of sustained virologic response 12 weeks after planned end of treatment ( SVR12 ) were 79.2 % vs 36.1 % , respectively ( 43.8 % difference ; 95 % confidence interval , 34.6-53 .0 ; P < .001 ) .